Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial
Open accessThe DOI matches its Crossref record; 100 of the 104 references it cites were found in a registry or an index; 26 of the 52 sources its claims cite were checked for support.
Abstract
Introduction Women with breast cancer who do not adhere to adjuvant endocrine therapy (AET) have increased risks of mortality and recurrence. There are multiple barriers to AET adherence, including medication side-effects, beliefs about medication, memory and psychological distress. We developed four intervention components, each targeting a different barrier. This pilot trial is part of the preparation phase of the Multiphase Optimisation Strategy, and aims to establish key trial parameters, establish intervention component adherence, establish availability and feasibility of outcome and process data, estimate variability in planned outcome measures and estimate cost of developing and delivering each intervention component. Methods and analysis The four intervention components are as follows: short message service text reminders (target: memory); a written information leaflet (target: medication beliefs); a guided self-help Acceptance and Commitment Therapy programme (target: psychological flexibility to reduce distress) and a self-management website (target: side-effect management). To evaluate the feasibility of recruitment, acceptability of the intervention components and the availability of outcome data, we will conduct a multisite, exploratory pilot trial using a 2 4-1 fractional factorial design, with a nested process evaluation. We will randomise 80 women with early-stage breast cancer who have been prescribed AET to one of eight experimental conditions. This will determine the combination of intervention components they receive, ranging from zero to four, with all conditions receiving usual care. Key outcomes of interest include medication adherence and quality of life. Progression to the optimisation phase will be based on predefined criteria for consent rates, patient adherence to intervention components and availability of medication adherence data. Ethics and dissemination The study was reviewed by the Wales Research Authority Research Ethics Committee 3 (21/WA/0322). Written informed consent will be obtained from all patients before randomisation. The results of this trial will be disseminated in a peer-reviewed journal. Trial registration number ISRTCN10487576. © 2023 BMJ Publishing Group. All rights reserved.
Overview
CoChat Summary
## TL;DR
This paper is a protocol for the ROSETA pilot trial, which will test the feasibility of a 4-component behavioural package to support adjuvant endocrine therapy adherence in UK women with early-stage breast cancer. It uses a 24-1 fractional factorial design to estimate component adherence, data availability, variability in outcomes, and costs before deciding whether to proceed to an optimisation trial.
## Key findings
- The planned pilot will randomise 80 women with early-stage breast cancer to 8 experimental conditions (about 10 per condition) using a 24-1 fractional factorial design, with usual care in all groups.
- The intervention package has 4 components targeting different adherence barriers: SMS reminders, a medication beliefs leaflet, a guided self-help ACT programme, and a self-management website.
- Progression to the optimisation phase will be judged using predefined criteria including consent rates, patient adherence to intervention components, and availability of medication adherence data.
- The study’s primary objective is feasibility/parameter estimation rather than effectiveness; it will estimate rates of eligibility, recruitment, retention, and component adherence, and will present point estimates and 95% CIs for main and interaction effects on adherence and quality of life.
## Methods
- Design: Multisite, exploratory pilot fractional factorial trial with a nested mixed-methods process evaluation; participants are followed up at 2 and 4 months.
- Sample/data: 80 adult women using tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for early-stage (1–3a) breast cancer, recruited from five UK NHS hospitals through three routes.
- Analysis: Primarily descriptive statistics and confidence intervals rather than hypothesis testing; intention-to-treat analysis with adjustment for the stratification factor, plus qualitative interviews analyzed using a rapid evaluation approach.
## Limitations
- The paper states that the pilot will not examine effectiveness of the intervention components.
- As a protocol, it reports planned methods and outcomes rather than results; no effectiveness, feasibility, or acceptability findings are stated in the paper.
- Evident from the text: the trial has 80 participants total and is designed for feasibility/estimation, so it is not powered for definitive effectiveness conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 2 Not valid · 15 Not checked · 12 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
§ Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial > Introduction
What the sources say
- Disputedcites [10] matched to “Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review” (2012) sourceExperimental — accuracy not yet measured
The Results section reports adherence rates of 41–88% for tamoxifen, 50–91% for aromatase inhibitors, and 46–100% for studies combining therapies. The Discussion identifies 31–73% as the range for treatment discontinuation in clinical practice, not adherence. The source describes itself as a systematic review, not a meta-analysis. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Women with breast cancer who do not adhere to adjuvant endocrine therapy (AET) have increased risks of mortality and recurrence.”
- Also stated in: § Introduction · plain
“Low adherence to AET is linked with higher rates of recurrence and all-cause mortality.2–9”
§ Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial > Abstract > Introduction
What the sources say
- Partly supportedcites [2] matched to “Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence” (2016) sourceExperimental — accuracy not yet measured
The Discussion reports that patients who stopped endocrine treatment early had more disease-free-survival events, and Statistical Methods defines those events to include invasive recurrence or death from any cause. The paper analyzes the composite outcome, however; it does not establish that low adherence increased recurrence and all-cause mortality separately. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] matched to “Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer” (2010) source
- Not checked — no full text of the sourcecites [4] matched to “Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients” (2008) source
- Supportedcites [5] matched to “Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality” (2013) source
The Discussion states that low adherence is associated with increased all-cause mortality and that longer adherence is associated with lower recurrence risk. The Conclusion likewise links fewer years of high adherence with increased recurrence. These findings support the citing sentence as an association, not a causal claim. (LLM, conf=0.91)
- Partly supportedcites [6] matched to “Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer” (2008) sourceExperimental — accuracy not yet measured
The Discussion reports increased all-cause mortality among women with low adherence to tamoxifen, and the Conclusion says they are at greater risk of death. But the Discussion explicitly says breast cancer recurrence was omitted because the datasets did not record it. The study assessed tamoxifen, not adjuvant endocrine therapies generally. (LLM, conf=0.94)
- Partly supportedcites [7] matched to “The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study” (2013) sourceExperimental — accuracy not yet measured
The Results (Accelerated failure-time models for recurrence and death; page not provided) link low tamoxifen adherence to significantly shorter time to recurrence. The paper also reports an association between low tamoxifen adherence and all-cause mortality from prior studies, but its own analysis found no significant effect on the death outcomes it tested. Its study was limited to tamoxifen, so it does not establish the claim for adjuvant endocrine therapy generally. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [8] Winn, 2016, The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer, Pharmacoepidemiol Drug Saf source
- Not checked — no full text of the sourcecites [9] matched to “Mortality Impact of Less-than-Standard Therapy in Older Breast Cancer Patients” (2008) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Unintentional non-adherence, such as forgetting, may be more common than intentionally missing doses.14–16”
§ Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial > Introduction
What the sources say
- Supportedcites [14] Kimmick, 2015, Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy, Breast source
The Results (Sample Description) report that 58.9% of the 112 women taking adjuvant endocrine therapy reported unintentional non-adherence, versus 33.9% who reported intentional non-adherence. Forgetting medication on a busy day was reported by 56.3%, directly supporting the example in the claim. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [15] Wouters, 2014, Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence, Clin Breast Cancer source
- Not checked — no full text of the sourcecites [16] matched to “Intentional and non-intentional non-adherence to medication amongst breast cancer patients” (2006) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Forming medication taking habits can reduce reliance on memory and help sustain behaviour change.39–42”
§ Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial > Methods and analysis > Intervention components
What the sources say
- Not checked — no full text of the sourcecites [39] matched to “Habit Formation and Multiple Means to Goal Attainment: Repeated Retrieval of Target Means Causes Inhibited Access to Competitors” (2007) source
- Not checked — no full text of the sourcecites [40] Gardner B , Lally P . Modelling habit formation and its determinants. In: The psychology of habit: theory, mechanisms, change, and contexts. Cham: Springer International Publishing, 2018: 207–29. source
- Partly supportedcites [41] matched to “Making health habitual: the psychology of ‘habit-formation’ and general practice” (2012) sourceExperimental — accuracy not yet measured
The Making Healthy Habits section says habits can persist with minimal effort or deliberation, and Habit Formation and Health suggests habit-formation advice can promote long-term behaviour change. The paper discusses diet and activity habits, not medication-taking specifically; it also does not explicitly address reliance on memory. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [42] Lally, 2013, Promoting habit formation, Health Psychology Review source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among adequately powered trials of AET interventions, there are few positive findings.18–20”
§ Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial > Introduction
What the sources say
- Partly supportedcites [18] Hurtado-de-Mendoza, 2016, Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review, Clin Breast Cancer sourceExperimental — accuracy not yet measured
The Results (Studies; page unavailable) report that none of the five interventions showed a significant difference between intervention and comparison arms in its primary analysis. The Results (Adherence Interventions Summary; page unavailable) also report null primary-endpoint findings for two large trials. The review does not establish which trials were adequately powered, so that qualification is not supported by our copy. (LLM, conf=0.83)
- Partly supportedcites [19] Heiney, 2019, A systematic review of interventions to improve adherence to endocrine therapy, Breast Cancer Res Treat sourceExperimental — accuracy not yet measured
The Discussion reports that the four randomized trials generally did not find statistically significant improvements in endocrine-therapy adherence, apart from a difference by country in one study. The Risk of Bias section says several trials had large samples, but the review does not establish which trials were adequately powered; that qualifier is not supported by our copy. (LLM, conf=0.84)
- Supportedcites [20] Finitsis, 2019, Interventions to promote adherence to endocrine therapy among breast cancer survivors: a meta-analysis, Psychooncology source
The methodological-quality table (section 4.2, page not available) gives the two large trials, Hadji and Markopoulos, the highest power rating. The included-studies table (section 4.2, page not available) reports no adherence difference between intervention and control groups in either trial, supporting the claim that positive findings among adequately powered trials were few. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
16 more claims · 4 with their cited sources checked
Create a free account to see all 43 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 17
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Hoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D. G., Barbour, V., Macdonald, H., Johnston, M., et al. (2014) · BMJ · doi:10.1136/bmj.g1687 · Cited by 10,548
Michie, S., Richardson, M., Johnston, M., Abraham, C., Francis, J., Hardeman, W., Eccles, M. P., Cane, J., & Wood, C. E. (2013) · Annals of Behavioral Medicine · doi:10.1007/s12160-013-9486-6 · Cited by 7,629
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence
Morisky, D. E., Green, L. W., & Levine, D. M. (1986) · Medical Care · doi:10.1097/00005650-198601000-00007 · Cited by 5,317
Antony, M. M., Bieling, P. J., Cox, B. J., Enns, M. W., & Swinson, R. P. (1998) · Psychological Assessment · doi:10.1037/1040-3590.10.2.176 · Cited by 4,874
CONSORT 2010 statement: extension to randomised pilot and feasibility trials.
Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · BMJ · doi:10.1136/bmj.i5239 · Cited by 3,404
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
on behalf of the PAFS consensus group, Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0105-8 · Cited by 2,843
Planning health promotion programs an intervention mapping approach
Bartholomew, L. K., Parcel, G. S., Kok, G., & Gottlieb, N. (2006) · Research Publications (Maastricht University) · Cited by 2,310
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Free, C., Phillips, G., Galli, L., Watson, L., Felix, L., Edwards, P., Patel, V., & Haines, A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001362 · Cited by 1,766
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Leventhal, H., Diefenbach, M., & Leventhal, E. A. (1992) · Cognitive Therapy and Research · doi:10.1007/bf01173486 · Cited by 1,573
Horne, R., Chapman, S. C. E., Parham, R., Freemantle, N., Forbes, A., & Cooper, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080633 · Cited by 1,174
Lally, P., & Gardner, B. (2013) · Health Psychology Review · doi:10.1080/17437199.2011.603640 · Cited by 901
Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., Hilfrich, J., Kwasny, W., Menzel, C., Samonigg, H., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67059-6 · Cited by 879
Gardner, B., Abraham, C., Lally, P., & de Bruijn, G.-J. (2012) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-9-102 · Cited by 855
Teare, M. D., Dimairo, M., Shephard, N., Hayman, A., Whitehead, A., & Walters, S. J. (2014) · Trials · doi:10.1186/1745-6215-15-264 · Cited by 773
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease: A Meta-analysis
Thakkar, J., Kurup, R., Laba, T.-L., Santo, K., Thiagalingam, A., Rodgers, A., Woodward, M., Redfern, J., & Chow, C. K. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.7667 · Cited by 685
Rapid Techniques in Qualitative Research: A Critical Review of the Literature
Vindrola-Padros, C., & Johnson, G. A. (2020) · Qualitative Health Research · doi:10.1177/1049732320921835 · Cited by 634
Making health habitual: the psychology of ‘habit-formation’ and general practice
Gardner, B., Lally, P., & Wardle, J. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x659466 · Cited by 591
Sekhon, M., Cartwright, M., & Francis, J. J. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07577-3 · Cited by 541
Rolffs, J. L., Rogge, R. D., & Wilson, K. G. (2018) · Assessment · doi:10.1177/1073191116645905 · Cited by 504
Cancer incidence and mortality projections in the UK until 2035.
Smittenaar, C. R., Petersen, K. A., Stewart, K., & Moitt, N. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.304 · Cited by 495
Graham, C. D., Gouick, J., Krahé, C., & Gillanders, D. (2016) · Clinical Psychology Review · doi:10.1016/j.cpr.2016.04.009 · Cited by 476
Self-citationFinitsis, D. J., Pellowski, J. A., & Johnson, B. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088166 · Cited by 355
McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343
Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.029 · Cited by 310
Systematic review of the barriers affecting medication adherence in older adults
Yap, A. F., Thirumoorthy, T., & Kwan, Y. H. (2016) · Geriatrics & Gerontology International · doi:10.1111/ggi.12616 · Cited by 308
Owusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F., Prout, M., Yood, M. U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 300
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300
Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
Makubate, B., Donnan, P. T., Dewar, J. A., Thompson, A. M., & McCowan, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.116 · Cited by 298
Cella, D., & Fallowfield, L. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9548-1 · Cited by 286
Subjective cognitive dysfunction in breast cancer patients: a systematic review
Pullens, M. J. J., De Vries, J., & Roukema, J. A. (2010) · Psycho-Oncology · doi:10.1002/pon.1673 · Cited by 274
Collins, L. M. (2018) · Statistics for Social and Behavioral Sciences · doi:10.1007/978-3-319-72206-1 · Cited by 257
Cella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, G., Howell, A., & On behalf of the ATAC Trialistsȁ9 Group (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9260-6 · Cited by 252
The impact of cognitive function on medication management: Three studies.
Stilley, C. S., Bender, C. M., Dunbar-Jacob, J., Sereika, S., & Ryan, C. M. (2010) · Health Psychology · doi:10.1037/a0016940 · Cited by 248
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245
Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8619 · Cited by 244
Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
Chlebowski, R. T., Kim, J., & Haque, R. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0389 · Cited by 192
Modelling Habit Formation and Its Determinants
Gardner, B., & Lally, P. (2018) · The Psychology of Habit · doi:10.1007/978-3-319-97529-0_12 · Cited by 187
Bjelic‐Radisic, V., Cardoso, F., Cameron, D., Brain, E. G. C., Kuljanić, K., da Costa, R. A., Conroy, T., Inwald, E., Serpentini, S., Pinto, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.027 · Cited by 177
Self-citationDezentjé, V. O., van Blijderveen, N. J. C., Gelderblom, H., Putter, H., van Herk-Sukel, M. P. P., Casparie, M. K., Egberts, A. C. G., Nortier, J. W. R., & Guchelaar, H.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0894 · Cited by 163
Mortality Impact of Less-than-Standard Therapy in Older Breast Cancer Patients
Yood, M. U., Owusu, C., Buist, D. S. M., Geiger, A. M., Field, T. S., Thwin, S. S., Lash, T. L., Prout, M. N., Wei, F., Quinn, V. P., et al. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.07.015 · Cited by 155
Moon, Z., Moss-Morris, R., Hunter, M. S., Carlisle, S., & Hughes, L. D. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s126651 · Cited by 148
The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
McCowan, C., Wang, S., Thompson, A. M., Makubate, B., & Petrie, D. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.464 · Cited by 137
Peddie, N., Agnew, S., Crawford, M., Dixon, D. L., Macpherson, I. R., & Fleming, L. (2021) · The Breast · doi:10.1016/j.breast.2021.05.005 · Cited by 137
Gold, M., Dunn, L. B., Phoenix, B., Paul, S. M., Hamolsky, D., Levine, J. D., & Miaskowski, C. (2016) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2015.06.003 · Cited by 134
Cohen, S. R., Sawatzky, R., Russell, L. B., Shahidi, J., Heyland, D. K., & Gadermann, A. M. (2017) · Palliative Medicine · doi:10.1177/0269216316659603 · Cited by 129
Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients
Ma, A. M. T., Barone, J., Wallis, A. E., Wu, N. J., Garcia, L. B., Estabrook, A., Rosenbaum-Smith, S. M., & Tartter, P. I. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2008.06.027 · Cited by 115
Sexual Problems During the First 2 Years of Adjuvant Treatment with Aromatase Inhibitors
Schover, L. R., Baum, G. P., Fuson, L. A., Brewster, A., & Melhem-Bertrandt, A. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12684 · Cited by 112
Understanding tamoxifen adherence in women with breast cancer: A qualitative study
Moon, Z., Moss‐Morris, R., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12266 · Cited by 112
Ganz, P. A., Petersen, L., Bower, J. E., & Crespi, C. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3866 · Cited by 103
Nestoriuc, Y., von Blanckenburg, P., Schuricht, F., Barsky, A. J., Hadji, P., Albert, U.-S., & Rief, W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw266 · Cited by 103
Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis
Underwood, E. A., Rochon, P. A., Moineddin, R., Lee, P. E., Wu, W., Pritchard, K. I., & Tierney, M. C. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4627-4 · Cited by 101
Brett, J., Fenlon, D., Boulton, M., Hulbert-Williams, N. J., Walter, F. M., Donnelly, P., Lavery, B., Morgan, A., Morris, C., & Watson, E. (2018) · European Journal of Cancer Care · doi:10.1111/ecc.12601 · Cited by 98
Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer
Kirk, M. C., & Hudis, C. A. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.016 · Cited by 96
Danner, U. N., Aarts, H., & de Vries, N. K. (2007) · Personality and Social Psychology Bulletin · doi:10.1177/0146167207303948 · Cited by 92
O'Neill, L., Latchford, G., McCracken, L. M., & Graham, C. D. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.08.008 · Cited by 87
Self-citationCahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84
Hurtado-de-Mendoza, A., Cabling, M. L., Lobo, T., Dash, C., & Sheppard, V. B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.006 · Cited by 79
Toivonen, K., Williamson, T., Carlson, L., Walker, L., & Campbell, T. (2020) · Cancers · doi:10.3390/cancers13010107 · Cited by 77
Brett, J., Boulton, M. G., Fenlon, D., Hulbert-Williams, N., Walter, F. M., Donnelly, P., Lavery, B. A., Morgan, A. A., Morris, C., & Watson, E. K. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s145784 · Cited by 73
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy
Kimmick, G., Edmond, S. N., Bosworth, H. B., Peppercorn, J., Marcom, P. K., Blackwell, K., Keefe, F. J., & Shelby, R. A. (2015) · The Breast · doi:10.1016/j.breast.2015.06.010 · Cited by 72
Clancy, C., Lynch, J., O'Connor, P. M., & Dowling, M. (2019) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2019.101706 · Cited by 70
A systematic review of interventions to improve adherence to endocrine therapy
Heiney, S. P., Parker, P. D., Felder, T. M., Adams, S. A., Omofuma, O. O., & Hulett, J. M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5012-7 · Cited by 69
Peate, M., Saunders, C. M., Cohen, P. A., & Hickey, M. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06117-7 · Cited by 69
Finitsis, D. J., Vose, B. A., Mahalak, J. G., & Salner, A. L. (2019) · Psycho-Oncology · doi:10.1002/pon.4959 · Cited by 68
Guastaferro, K., & Collins, L. M. (2019) · American Journal of Public Health · doi:10.2105/ajph.2018.304874 · Cited by 66
Iterative Cycles in Qualitative Research: Introducing the RREAL Sheet as an Innovative ProcessPreprint
Vindrola‐Padros, C., Chisnall, G., Polanco, N., & Juan, N. V. S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4162797 · Cited by 66
Martino, G., Catalano, A., Agostino, R. M., Bellone, F., Morabito, N., Lasco, C. G., Vicario, C. M., Schwarz, P., & Feldt-Rasmussen, U. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230681 · Cited by 61
Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. L., & Macpherson, I. R. (2022) · The Breast · doi:10.1016/j.breast.2022.04.010 · Cited by 59
Winn, A. N., & Dusetzina, S. B. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4012 · Cited by 57
Smith, S. G., Sestak, I., Howell, A., Forbes, J., & Cuzick, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7439 · Cited by 51
Self-citationWouters, H., Stiggelbout, A. M., Bouvy, M. L., Maatman, G. A., Van Geffen, E. C. G., Vree, R., Nortier, J. W., & Van Dijk, L. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.04.005 · Cited by 46
Collins, L. M., Strayhorn, J. C., & Vanness, D. J. (2021) · Translational Behavioral Medicine · doi:10.1093/tbm/ibab087 · Cited by 45
Voils, C. I., King, H. A., Thorpe, C. T., Blalock, D. V., Kronish, I. M., Reeve, B. B., Boatright, C., & Gellad, Z. F. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05621-7 · Cited by 44
Jacobs, J. M., Walsh, E. A., Park, E. R., Berger, J., Peppercorn, J. M., Partridge, A. H., Horick, N., Safren, S. A., Temel, J. S., & Greer, J. A. (2020) · International Journal of Behavioral Medicine · doi:10.1007/s12529-020-09908-2 · Cited by 44
Guastaferro, K., & Collins, L. M. (2021) · Implementation Research and Practice · doi:10.1177/26334895211054363 · Cited by 42
Pan, Y., Heisig, S. R., von Blanckenburg, P., Albert, U., Hadji, P., Rief, W., & Nestoriuc, Y. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4637-2 · Cited by 40
Green, S. M. C., French, D., Graham, C. D., Hall, L., Rousseau, N. S., Foy, R., Clark, J., Parbutt, C., Raine, E., Gardner, B., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08243-4 · Cited by 38
Self-citationOncology providers’ perspectives on endocrine therapy prescribing and management
Wheeler, S., Roberts, M., Bloom, D., Reeder-Hayes, K., Espada, M., Peppercorn, J., Golin, C., & Earp, J. A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s95594 · Cited by 31
Brett, J., Hulbert-Williams, N., Fenlon, D., Boulton, M. G., Walter, F. M., Donnelly, P., Lavery, B. A., Morgan, A. A., Morris, C., Horne, R., et al. (2017) · Health Psychology Open · doi:10.1177/2055102917740469 · Cited by 29
Greene, A., Elmer, M. E., Ludlam, S., Shay, K., Bentley, S., Trennery, C., Grimes, R., & Gater, A. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00179-3 · Cited by 29
Rose, M., Graham, C. D., O'Connell, N., Vari, C., Edwards, V., Taylor, E., McCracken, L. M., Radunovic, A., Rakowicz, W., Norton, S., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291722000083 · Cited by 28
Self-citationSestak, I., Smith, S. G., Howell, A., Forbes, J. F., & Cuzick, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx713 · Cited by 27
Self-citationMobile-based oral chemotherapy adherence-enhancing interventions: scoping review
Skrabal Ross, X., Gunn, K. M., Patterson, P., & Olver, I. (2018) · JMIR mhealth and uhealth · doi:10.2196/11724 · Cited by 24
Hall, L., King, N. V., Graham, C. D., Green, S. M. C., Barber, A., Neal, R. D., Foy, R., Clark, J., Lloyd, K. E., & Smith, S. G. (2021) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01114-7 · Cited by 24
Self-citationOutlining an Acceptance and Commitment Therapy approach to treatment non‐adherence
Graham, C. D., McCracken, L. M., Harrison, A., Walburn, J., & Weinman, J. (2022) · British Journal of Health Psychology · doi:10.1111/bjhp.12579 · Cited by 22
Self-citationMeggetto, O., Maunsell, E., Chlebowski, R. T., Goss, P. E., Tu, D., & Richardson, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.8895 · Cited by 21
Hall, L. H., Clark, J., Smith, S. G., Graham, C. D., & for the ACTION investigators (2022) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2021.1955318 · Cited by 10
Self-citationGreen, S. M. C., Hall, L., Rousseau, N. S., French, D., Graham, C. D., Collinson, M., Mason, E. D., Wilkes, H., Howdon, D., Foy, R., et al. (2023) · NIHR Open Research · doi:10.3310/nihropenres.13337.2 · Cited by 10
Self-citationGreen, S. M. C., French, D., Hall, L., Bartlett, Y. K., Rousseau, N. S., Raine, E., Parbutt, C., Gardner, B., ROSETA Investigators, & Smith, S. G. (2023) · Journal of Medical Internet Research · doi:10.2196/38073 · Cited by 7
Self-citationGreen, S. M. C., French, D., Graham, C. D., Hall, L., Rousseau, N. S., Foy, R., Clark, J., Parbutt, C., Raine, E., Gardner, B., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1239166/v1 · Cited by 6
Self-citationGreen, S. M. C., FRENCH, D. P., Hall, L., et al. (2022) · doi:10.2196/preprints.38073 · Cited by 2
Self-citation
Cited by
Smyth, E., Brennan, L. K., Enright, R. H., Sekhon, M., Dickson, J., Hussey, J. M., & Guinan, E. M. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08574-4 · Cited by 22
Green, S. M. C., French, D., Hall, L., Bartlett, Y. K., Rousseau, N. S., Raine, E., Parbutt, C., Gardner, B., ROSETA Investigators, & Smith, S. G. (2023) · Journal of Medical Internet Research · doi:10.2196/38073 · Cited by 7
“The studies in this paper form part of a broader research program, which aimed to develop and optimize a multicomponent intervention to support adherence to AET in women with breast cancer [26,55].”
Self-citationGreen, S. M. C., Hall, L., Rousseau, N. S., French, D., Graham, C. D., Collinson, M., Mason, E. D., Wilkes, H., Howdon, D., Foy, R., et al. (2023) · NIHR Open Research · doi:10.3310/nihropenres.13337.2 · Cited by 10
“These are described in detail elsewhere (45){Smith, 2023 #560}.””
InfluentialSelf-citationWalsh, E. A., Post, K. E., Massad, K., Horick, N., Antoni, M. H., Penedo, F. J., Safren, S. A., Partridge, A. H., Peppercorn, J. M., Park, E. R., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07228-z · Cited by 7
“Existing medication adherence programs for other medical populations (e.g., HIV) are also being adapted to target AET adherence, and other intervention trials are currently on-going [18, 19, 23].”
Reimagining Medication Adherence: A Novel Holistic Model for Hypertension Therapy
Schäfer, C. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s442645 · Cited by 8
“…area perspective, recently published broad multi-factor studies on medication adherence in various conditions include the context of stroke, 15 type 2 diabetes mellitus, 16,17 breast cancer, 18 tuberculosis 19 and medication, but not in the context of hypertension, which this study investigates.”
Background
Metadata
- Authors
- Smith, S. G., Green, S. M. C., Ellison, R., Foy, R., Graham, C. D., Mason, E., French, D. P., Hall, L. H., Wilkes, H., McNaught, E., Raine, E., Walwyn, R., Howdon, D., Clark, J., Rousseau, N., Buxton, J., Moore, S. J. L., Parbutt, C., Velikova, G., Farrin, A., & Collinson, M.
- Affiliations
- University of Leeds (GB)
- Queen's University Belfast (GB)
- University of Manchester (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- Smith, Samuel G
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2023-02
- Volume
- 13
- Issue
- 2
- Pages
- e069971
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC9900066
- OpenAlex
- W4319078409
- Cited by
- 20
- References
- 104
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 9 · 2023: 7
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- BMJ Open (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Research Portal (Queen's University Belfast) (acceptedVersion, cc-by)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion, cc-by-nc-nd)
- Research Explorer (The University of Manchester) (acceptedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Manchester Biomedical Research Centre (IS-BRC-1215-20007)
- National Institute of Health (N/A)
- Yorkshire Cancer Research (L417, N/A)
- National Institute for Health (NIHR300588)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Keywords
- breast cancer, adjuvant endocrine therapy, medication adherence, behavioral interventions, SMS reminders, medication beliefs, acceptance and commitment therapy, guided self-help, side effect management, psychological distress, quality of life, early breast cancer, intervention optimization, feasibility
- MeSH terms
- Breast Neoplasms, Female, United Kingdom, Humans, Quality of Life, Randomized Controlled Trials as Topic, Medication Adherence, Acceptance and Commitment Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.